{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:25:00Z","timestamp":1791599100720,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13760-024-02518-9","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:08:47Z","timestamp":1711764527000},"page":"1237-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain\u2013Barr\u00e9 syndrome patients who poorly responded to initial IVIG cycle: a systematic review"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-7321","authenticated-orcid":false,"suffix":"Jr.","given":"Mario B.","family":"Prado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Joy B.","family":"Adiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Wilson R.","family":"Turalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin A.","family":"Dasig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"2518_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12594","author":"PA van Doorn","year":"2023","unstructured":"van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ (2023) European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of <scp>Guillain\u2013Barr\u00e9<\/scp> syndrome. J Peripher Nerv Syst. https:\/\/doi.org\/10.1111\/jns.12594","journal-title":"J Peripher Nerv Syst"},{"key":"2518_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577572","volume":"355","author":"MB Prado","year":"2021","unstructured":"Prado MB, Narito KM, Adiao KJB (2021) Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever. J Neuroimmunol 355:577572. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577572","journal-title":"J Neuroimmunol"},{"key":"2518_CR3","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome. Ann Neurol 27:S21\u2013S24. https:\/\/doi.org\/10.1002\/ana.410270707","journal-title":"Ann Neurol"},{"key":"2518_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/jnnp-2013-306212","volume":"85","author":"JS Bae","year":"2014","unstructured":"Bae JS, Yuki N, Kuwabara S, Kim JK, Vucic S, Lin CS, Kiernan MC (2014) Guillain-Barr\u00e9 syndrome in Asia. J Neurol Neurosurg Psychiatry 85:905\u2013911. https:\/\/doi.org\/10.1136\/jnnp-2013-306212","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2518_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1529-8027.2011.00338.x","volume":"16","author":"MA Albert","year":"2011","unstructured":"Albert MA, Alentorn A, Martinez-Yelamos S, Martinez-Matos JA, Povedano M, Montero J, Casasnovas C (2011) Very early electrodiagnostic findings in Guillain-Barr\u00e9 syndrome. J Peripher Nervous Syst 16:136\u2013142. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00338.x","journal-title":"J Peripher Nervous Syst"},{"key":"2518_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cen3.12343","volume":"7","author":"S Kuwabara","year":"2016","unstructured":"Kuwabara S, Misawa S (2016) Future treatment for Guillain-Barr\u00e9 syndrome. Clin Exp Neuroimmunol 7:320\u2013323. https:\/\/doi.org\/10.1111\/cen3.12343","journal-title":"Clin Exp Neuroimmunol"},{"key":"2518_CR7","doi-asserted-by":"publisher","unstructured":"R.A.C. Hughes, A. V. Swan, P.A. van Doorn, Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome, Cochrane Database of Systematic Reviews 2014 (2014). https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6.","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"2518_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1474-4422(13)70215-1","volume":"12","author":"S Kuwabara","year":"2013","unstructured":"Kuwabara S, Yuki N (2013) Axonal Guillain-Barr\u00e9 syndrome\u202f: concepts and controversies. Lancet Neurol 12:1180\u20131188. https:\/\/doi.org\/10.1016\/S1474-4422(13)70215-1","journal-title":"Lancet Neurol"},{"key":"2518_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1212\/WNL.0000000000013139","volume":"98","author":"AY Doets","year":"2022","unstructured":"Doets AY, Lingsma HF, Walgaard C, Islam B, Papri N, Davidson A, Yamagishi Y, Kusunoki S, Dimachkie MM, Waheed W, Kolb N, Islam Z, Mohammad QD, Harbo T, Sindrup SH, Chavada G, Willison HJ, Casasnovas C, Bateman K, Miller JAL, van den Berg B, Verboon C, Roodbol J, Leonhard SE, Benedetti L, Kuwabara S, van den Bergh P, Monges S, Marfia GA, Shahrizaila N, Galassi G, P\u00e9r\u00e9on Y, B\u00fcrmann J, Kuitwaard K, Kleyweg RP, Marchesoni C, Sedano Tous MJ, Querol L, Illa I, Wang Y, Nobile-Orazio E, Rinaldi S, Schenone A, Pardo J, Vermeij FH, Lehmann HC, Granit V, Cavaletti G, Guti\u00e9rrez-Guti\u00e9rrez G, Barroso FA, Visser LH, Katzberg HD, Dardiotis E, Attarian S, van der Kooi AJ, Eftimov F, Wirtz PW, Samijn JPA, Jacobus Gilhuis H, Hadden RDM, Holt JKL, Sheikh KA, Karafiath S, Vytopil M, Antonini G, Feasby TE, Faber CG, Gijsbers CJ, Busby M, Roberts RC, Silvestri NJ, Fazio R, van Dijk GW, Garssen MPJ, Straathof CSM, Gorson KC, Jacobs BC (2022) Predicting outcome in Guillain-Barr\u00e9 syndrome international validation of the modified erasmus GBS outcome score. Neurology 98:518\u2013532. https:\/\/doi.org\/10.1212\/WNL.0000000000013139","journal-title":"Neurology"},{"key":"2518_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, De Gelder J, Tio-Gillen AP, Hop WCJ, Van Gelder T, Van Toorenenbergen AW, Van Doorn PA, Jacobs BC (2009) Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome. Ann Neurol 66:597\u2013603. https:\/\/doi.org\/10.1002\/ana.21737","journal-title":"Ann Neurol"},{"key":"2518_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Randomised trial of plasma exchange","year":"1997","unstructured":"Randomised trial of plasma exchange (1997) Intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. The Lancet 349:225\u2013230. https:\/\/doi.org\/10.1016\/S0140-6736(96)09095-2","journal-title":"The Lancet"},{"key":"2518_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","volume":"350","author":"P Farcas","year":"1997","unstructured":"Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I (1997) Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome. The Lancet 350:1747","journal-title":"The Lancet"},{"key":"2518_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1590\/0004-282X20150136","volume":"73","author":"DA Godoy","year":"2015","unstructured":"Godoy DA, Rabinstein A (2015) Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barr\u00e9 syndrome? Arq Neuropsiquiatr 73:848\u2013851. https:\/\/doi.org\/10.1590\/0004-282X20150136","journal-title":"Arq Neuropsiquiatr"},{"key":"2518_CR14","doi-asserted-by":"publisher","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group (2021) Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20(4):275\u2013283. https:\/\/doi.org\/10.1016\/S1474-4422(20)30494-4","DOI":"10.1016\/S1474-4422(20)30494-4"},{"key":"2518_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","volume":"91","author":"C Verboon","year":"2020","unstructured":"Verboon C, Van Den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, Lingsma H, Van Den Bergh P, Harbo T, Bateman K, Pereon Y, Sindrup SH, Kusunoki S, Miller J, Islam Z, Hartung HP, Chavada G, Jacobs BC, Hughes RAC, Van Doorn PA (2020) Original research: second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry 91:113\u2013121. https:\/\/doi.org\/10.1136\/jnnp-2019-321496","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2518_CR16","doi-asserted-by":"publisher","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","DOI":"10.1001\/jama.283.15.2008"},{"key":"2518_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"The BMJ"},{"key":"2518_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online). https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ (Online)"},{"key":"2518_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jns.12286","volume":"23","author":"C Walgaard","year":"2018","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA, de Wit MCY, van den Berg B, Doets AY, Leonhard SE, Verboon JC, van Woerkom M, Tio-Gillen AP, van Rijs W, Huizinga H, Badrising UA, Bienfait HME, Blom RJ, van Boheemen CJM, Breukelman AJ, Bronner IM, Dieks HJG, van Dijk GW, van Engelen BGM, Faber CG, Feenstra B, Fokke C, Garssen MPJ, Gijsbers CJ, Gilhuis HJ, van der Graaff MM, Groen RJ, Hoogendoorn TA, Hovestad A, Jansen PJHW, Jellema K, Keuter E, Kleyweg RP, van Koningsveld R, van der Kooi AJ, van der Kooi EL, Krudde J, Kuks JBM, Kuitwaard K, Linssen WHJP, Lion J, Lovenich H, Manschot SM, Mellema SJ, Merkies ISJ, van der Meulen MFG, van der Meulen WDM, Molenaar DSM, Oenema DG, van Oosten BW, van Oostrom JCH, van Orshoven NP, van der Ploeg RJO, van der Pol WL, Polman S, van der Ree TC, de Rijk MC, Ruitenberg A, Ruts L, Samijn JPA, Schyns-Soeterboek AJGM, Stevens M, Vermeij FH, Verschuuren JJGM, Visser LH, Wirtz PW, Wohlgemuth M, Zwetsloot CP, Dippel DWJ, Hintzen RQ (2018) Second IVIg course in Guillain-Barr\u00e9 syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 23:210\u2013215. https:\/\/doi.org\/10.1111\/jns.12286","journal-title":"J Peripher Nerv Syst"},{"key":"2518_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s1695-4033(03)77997-1","volume":"58","author":"A Criado Molina","year":"2003","unstructured":"Criado Molina A, P\u00e9rez Navero JL, Fr\u00edas P\u00e9rez MA, Ant\u00f3n Gamero M, Ibarra de la Rosa I (2003) S\u00edndrome de Guillain-Barr\u00e9 prolongado. An Pediatr (Engl Ed) 58:74\u201376. https:\/\/doi.org\/10.1016\/s1695-4033(03)77997-1","journal-title":"An Pediatr (Engl Ed)"},{"key":"2518_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jocn.2020.04.100","volume":"77","author":"J Yang","year":"2020","unstructured":"Yang J, Jia R (2020) Is a second course of intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome justifiable?: GBS and albumin. J Clin Neurosci 77:251\u2013252. https:\/\/doi.org\/10.1016\/j.jocn.2020.04.100","journal-title":"J Clin Neurosci"},{"key":"2518_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98501-y","author":"J Rath","year":"2021","unstructured":"Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, Zimprich F (2021) Real-world treatment of adult patients with Guillain-Barr\u00e9 syndrome over the last two decades. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-98501-y","journal-title":"Sci Rep"},{"key":"2518_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/1941874419893570","volume":"10","author":"H Algahtani","year":"2020","unstructured":"Algahtani H, Shirah B, Alrefaei K, Albassam M, Abdelghaffar N (2020) Are repeated cycles of intravenous immunoglobulin justified in patients with poorly responsive Guillain-Barr\u00e9 syndrome? Neurohospitalist 10:224\u2013228. https:\/\/doi.org\/10.1177\/1941874419893570","journal-title":"Neurohospitalist"},{"key":"2518_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119840195","author":"AM Alboudi","year":"2019","unstructured":"Alboudi AM, Sarathchandran P, Geblawi SS, Kayed DM, Inshasi J, Purayil SP, Almadani AB, Katirji B (2019) Rescue treatment in patients with poorly responsive Guillain-Barre syndrome. SAGE Open Med. https:\/\/doi.org\/10.1177\/2050312119840195","journal-title":"SAGE Open Med"},{"key":"2518_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120368","author":"P Faustino","year":"2022","unstructured":"Faustino P, Coutinho M, Brum M, Medeiros L, Ladeira F (2022) Outcomes in Guillain-Barr\u00e9 syndrome following a second therapeutic cycle\u2014a single-centre retrospective observational study. J Neurol Sci. https:\/\/doi.org\/10.1016\/j.jns.2022.120368","journal-title":"J Neurol Sci"},{"key":"2518_CR26","first-page":"48","volume":"34","author":"A Rodriguez-Lozano","year":"2013","unstructured":"Rodriguez-Lozano A (2013) Retreatment with IVIG of refractory Guillain Barre syndrome in children. Acta Pedi\u00e1trica de M\u00e9xico 34:48\u201350","journal-title":"Acta Pedi\u00e1trica de M\u00e9xico"},{"key":"2518_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-101","author":"JL Winters","year":"2011","unstructured":"Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C (2011) Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome. BMC Health Serv Res. https:\/\/doi.org\/10.1186\/1472-6963-11-101","journal-title":"BMC Health Serv Res"},{"key":"2518_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.01.057","author":"M Prado","year":"2020","unstructured":"Prado M, Jamora RD (2020) Cost of Parkinson\u2019s disease among Filipino patients seen at a public tertiary hospital in Metro Manila. J Clin Neurosci. https:\/\/doi.org\/10.1016\/j.jocn.2020.01.057","journal-title":"J Clin Neurosci"},{"key":"2518_CR29","unstructured":"Philhealth (2017) List of Medical Case Rates. https:\/\/www.philhealth.gov.ph\/"},{"key":"2518_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.879287","author":"JL Lee","year":"2022","unstructured":"Lee JL, Mohd Saffian S, Makmor-Bakry M, Islahudin F, Alias H, Ali A, Mohamed Shah N (2022) Prescribing practices of intravenous immunoglobulin in tertiary care hospitals in malaysia: a need for a national guideline for immunoglobulin use. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.879287","journal-title":"Front Pharmacol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02518-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02518-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02518-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:44:31Z","timestamp":1721789071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02518-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02518-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors declare they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This is a systematic review. The UPM Research Ethics Committee has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/a.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human or animals"}},{"value":"N\/a.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}